United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.04 USD
+8.81 (2.73%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $330.84 -0.20 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 301 - 320 ( 601 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Believe EV Interim in Sept Likely to Be Study Continuation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Biotechnology - The Week Ahead in Life Sciences: Upcoming Events for the Week of July 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials--Top-line Miss and Bottom-line Beat: Return to Revenue Growth Anticipated in 2017; Reiterate OUTPERFORM but Reducing PT to $213
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Post-IPR Update: Thinking Through a Possible Appeal Process and Implications of New Patents
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Statistical Deep Dive Into the Upcoming FREEDOM-EV Interim Look
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Negative IPR for ''393 Patent Expected and Appealable--RemoSync Has Another Delay but RemoPro is on the Way; Reiterate OUTPERFORM and $229 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L